Whether it's uveitis, post‑surgery inflammation, or allergic conjunctivitis, anti‑inflammatory drugs are the go‑to. The ophthalmic drugs market research shows that anti‑inflammatories hold the largest share, driven by corticosteroid eye drops (prednisolone, dexamethasone) and NSAIDs (ketorolac, bromfenac). They're cheap, effective, and widely available. But long‑term steroid use can cause cataracts and glaucoma — a real problem.
What's new? Non‑steroidal immunomodulators (cyclosporine, lifitegrast) for dry eye — they target inflammation without steroid side effects. The ophthalmic drugs market trends highlight that dry eye is the fastest‑growing application, driven by screen time, contact lens use, and aging. Xiidra and Restasis are blockbusters.
But anti‑inflammatories are not for everyone. Some patients need antibiotics (for infection) or glaucoma drugs (for pressure). The key is getting the right diagnosis.
The message: if your eyes are red and painful, don't just buy over‑the‑counter drops. See a doctor. You might need a prescription steroid — or you might have something more serious.
